DexCom, Inc. (DXCM) Stock Analysis

DexCom is a San Diego-based medical device company in the healthcare sector that builds continuous glucose monitoring systems. Incorporated in 1999, the business sells wearable sensors like the Dexcom G6, G7, and Dexcom ONE+ to replace painful daily fingerstick tests for people managing diabetes. They market these devices and companion tracking software directly to endocrinologists, physicians, and diabetes educators. Recently, they expanded beyond prescription users with Stelo, a biosensor targeting adults with prediabetes and Type 2 diabetes who do not use insulin.

DexCom operates as an established heavyweight in what is essentially a duopoly, capturing roughly 33.9% of the continuous glucose monitoring revenue market. Their primary rival is Abbott Laboratories, which leads the category with a 52.8% market share through its FreeStyle Libre line, while Medtronic trails at about 10.1%. DexCom’s core edge rests on high sensor accuracy and seamless insulin pump integrations, creating strong brand loyalty among intensive insulin users. However, Abbott’s aggressive pricing and mass-market distribution remain serious ongoing threats to DexCom’s pricing power.

DexCom is shifting from hyper-growth mode into a steady, mature expansion phase. Annual revenue reached $4.03 billion in 2024, an 11% increase over 2023, following a stronger 24% surge to $3.62 billion the year prior. To keep top-line growth in double digits, management is pivoting into the broader metabolic health space by launching Stelo as an over-the-counter option. Targeting the massive non-insulin Type 2 and prediabetes demographics is a necessary strategic play before their core prescription customer base fully saturates.